Država: Sjedinjene Američke Države
Jezik: engleski
Izvor: NLM (National Library of Medicine)
Ofloxacin (UNII: A4P49JAZ9H) (Ofloxacin - UNII:A4P49JAZ9H)
Akorn
Ofloxacin
Ofloxacin 3 mg in 1 mL
OPHTHALMIC
PRESCRIPTION DRUG
Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: Ofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication (see WARNINGS ).
Ofloxacin Ophthalmic Solution USP, 0.3% is supplied sterile in plastic dropper bottles with tan polypropylene cap of the following sizes: STORAGE: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. AKORN Manufactured by: Akorn, Inc. Lake Forest, IL 60045 Made in Switzerland 83100103
Abbreviated New Drug Application
OFLOXACIN- OFLOXACIN SOLUTION/ DROPS AKORN ---------- PRESCRIBING INFORMATION OFLOXACIN OPHTHALMIC SOLUTION USP, 0.3% Rx only DESCRIPTION Ofloxacin Ophthalmic Solution USP, 0.3% is a sterile ophthalmic solution. It is a fluorinated carboxyquinolone anti-infective for topical ophthalmic use. CHEMICAL NAME: (±)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo- 7_H_-pyrido [1,2,3-_de_]-1,4-benzoxazine-6-carboxylic acid. CONTAINS: ACTIVE: ofloxacin 0.3% (3 mg/mL); PRESERVATIVE: benzalkonium chloride (0.005%); INACTIVES: sodium chloride and water for injection. May also contain hydrochloric acid and/or sodium hydroxide to adjust pH. Ofloxacin Ophthalmic Solution USP, 0.3% is unbuffered and formulated with a pH of 6.4 (range - 6.0 to 6.8). It has an osmolality of 300 mOsm/kg. Ofloxacin is a fluorinated 4- quinolone which differs from other fluorinated 4-quinolones in that there is a six member (pyridobenzoxazine) ring from positions 1 to 8 of the basic ring structure. CLINICAL PHARMACOLOGY PHARMACOKINETICS: Serum, urine and tear concentrations of ofloxacin were measured in 30 healthy women at various time points during a ten-day course of treatment with ofloxacin ophthalmic solution. The mean serum ofloxacin concentration ranged from 0.4 ng/mL to 1.9 ng/mL. Maximum ofloxacin concentration increased from 1.1 ng/mL on day one to 1.9 ng/mL on day 11 after QID dosing for 10 1/2 days. Maximum serum ofloxacin concentrations after ten days of topical ophthalmic dosing were more than 1000 times lower than those reported after standard oral doses of ofloxacin. Tear ofloxacin concentrations ranged from 5.7 to 31 mcg/g during the 40 minute period following the last dose on day 11. Mean tear concentration measured four hours after topical ophthalmic dosing was 9.2 mcg/g. Corneal tissue concentrations of 4.4 mcg/mL were observed four hours after beginning topical ocular application of two drops of ofloxacin ophthalmic solution every 30 minutes. Ofloxacin was excreted in the urine primarily unmodified. MICROBIOLOGY: Pročitajte cijeli dokument